<DOC>
	<DOCNO>NCT00006773</DOCNO>
	<brief_summary>Phase I trial study effectiveness bortezomib treat patient recurrent glioma . Bortezomib may stop growth tumor cell block enzymes necessary tumor cell growth</brief_summary>
	<brief_title>Bortezomib Treating Patients With Recurrent Glioma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose bortezomib without anticonvulsant drug know metabolized P450 hepatic enzyme complex patient recurrent glioma . II . Determine biologic activity drug measure proteasome 20S activity patient . III . Determine effect hepatic enzyme-inducing drug , anticonvulsant , biologic activity drug patient . OUTLINE : This dose-escalation , multicenter study . Patients stratify accord concurrent anticonvulsant drug use ( phenytoin , carbamazepine , phenobarbital , primidone , felbamate v gabapentin , lamotrigine , valproic acid , anticonvulsant drug ) . Patients receive bortezomib IV 3-5 second twice weekly 2 week . Courses repeat every 3 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos bortezomib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , 10 additional patient treat bortezomib MTD . Patients follow every 2 month .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Oligodendroglioma</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Histologically confirm progressive recurrent malignant glioma Anaplastic astrocytoma Anaplastic oligodendroglioma Glioblastoma multiforme Prior lowgrade glioma progress highgrade therapy allow Measurable disease MRI CT scan Performance status Karnofsky 60100 % Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Bilirubin great 1.5 mg/dL Transaminases great 4 time upper limit normal Creatinine great 1.7 mg/dL Mini mental score least 15 No concurrent serious infection medical illness would preclude study participation No malignancy within past 5 year except curatively treat basal cell squamous cell skin cancer carcinoma situ cervix breast Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study participation At least 4 week since prior chemotherapy ( 6 week nitrosoureas ) recover No 1 prior chemotherapy regimen At least 3 month since prior radiotherapy recover No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>